Literature DB >> 3875376

Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets.

E F Plow, R P McEver, B S Coller, V L Woods, G A Marguerie, M H Ginsberg.   

Abstract

Fibrinogen, fibronectin, von Willebrand factor, and thrombospondin are four large glycoproteins that bind to thrombin-stimulated platelets and influence cellular adhesive functions. The effects of five monoclonal antibodies that react with platelet membrane glycoproteins (GP) IIb and/or IIIa on the binding of these four molecules to stimulated platelets were assessed. Tab and PMI-1, antibodies recognizing GPIIb, had no effect, whereas 10E5 and 2G12, antibodies that immunoprecipitate both GPIIb and IIIa in the presence of calcium, inhibited binding of all four ligands by greater than 85%. T10, an antibody specific for the GPIIb-IIIa complex, produced partial inhibition (60% to 80%) of the binding of each ligand. Inhibitory antibodies were effective in the same dose range for all four proteins and also inhibited binding of fibrinogen, fibronectin, and von Willebrand factor to receptors fixed in an induced state (thrombin-stimulated platelets fixed with paraformaldehyde). Thrombospondin did not bind to these fixed cell preparations. The results suggest that these four adhesive proteins have a related mechanism of binding to thrombin-stimulated platelets. This related mechanism may entail the sharing of some, but not necessarily all, binding sites for the four ligands or a proximal relationship between these binding sites.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3875376

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

Review 1.  Platelet glycoprotein IIb/IIIa receptor antagonists: current concepts and future directions.

Authors:  J J Ferguson; M Zaqqa
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 2.  Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions.

Authors:  H Benjamin Starnes; Ankit A Patel; George A Stouffer
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

3.  Platelet Glycoprotein IIb/IIIa Integrin Blockade in Coronary Artery Disease: Current State of the Art.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

4.  Enhancement of thrombogenesis by plasma fibronectin cross-linked to fibrin and assembled in platelet thrombi.

Authors:  Jaehyung Cho; Deane F Mosher
Journal:  Blood       Date:  2006-01-03       Impact factor: 22.113

5.  Protein kinase C and cyclic AMP regulate reversible exposure of binding sites for fibrinogen on the glycoprotein IIB-IIIA complex of human platelets.

Authors:  G van Willigen; J W Akkerman
Journal:  Biochem J       Date:  1991-01-01       Impact factor: 3.857

6.  Structural requirements for biological activity of the ninth and tenth FIII domains of human fibronectin.

Authors:  R P Grant; C Spitzfaden; H Altroff; I D Campbell; H J Mardon
Journal:  J Biol Chem       Date:  1997-03-07       Impact factor: 5.157

Review 7.  The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend.

Authors:  Barry S Coller; Sanford J Shattil
Journal:  Blood       Date:  2008-10-15       Impact factor: 22.113

8.  Efficacy of enoxaparin, certoparin and dalteparin in preventing cardiac catheter thrombosis: an in vitro approach.

Authors:  Uwe Raaz; Michael Buerke; Marese Busshardt; Lars Maegdefessel; Alexander Plehn; Baerbel Hauroeder; Karl Werdan; Axel Schlitt
Journal:  J Thromb Thrombolysis       Date:  2010-04       Impact factor: 2.300

Review 9.  Integrin αIIbβ3: from discovery to efficacious therapeutic target.

Authors:  Kamila Bledzka; Susan S Smyth; Edward F Plow
Journal:  Circ Res       Date:  2013-04-12       Impact factor: 17.367

10.  Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo.

Authors:  M L Nierodzik; A Plotkin; F Kajumo; S Karpatkin
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.